Federal Register / Vol. 62, No. 163 / Friday, August 22, 1997 / Notices 44699

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 100 people.

Purpose: To provide an overview of the

implementation of the mortality study, and to

exchange information among government,

stakeholders, and interested parties on

procedural and related aspects of the study.

Matters To Be Discussed: The agenda will

include information on the NIOSH/NCI

research plan; request for information on

industrial hygiene sample measurements or

other data, or possible sources of such data

that could add to the study validity; request

for information on types and usage of diesel

engines and fuel of relevance to exposure

estimation; plan for data sharing and

announcement of future informational

meetings. Viewpoints and suggestions from

industry, labor, academia, other government

agencies, and the public are invited. Written

comments will also be considered.

Contact Person For Additional

Information: Michael Attfield, Ph.D., NIOSH

Project Director, Division of Respiratory

Disease Studies, NIOSH, CDC, M/S 234, 1095

Willowdale Road, Morgantown, West

Virginia 26505–2888, telephone 304/285–

5737, E-mail mda1@cdc.gov.

Individuals wishing to make an oral

statement should contact Dr. Attfield so that

time can be allocated.

Dated: August 19, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–22469 Filed 8–21–97; 8:45 am]

BILLING CODE 4160–19–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Vaccine Advisory Committee

National Vaccine Advisory Committee

(NVAC), Subcommittee on Vaccine

Safety, Subcommittee on Immunization

Coverage, Subcommittee on Future

Vaccines, and the Advisory Commission

on Childhood Vaccines (ACCV)

Subcommittee on Vaccine Safety:

Meetings.

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following Federal

advisory committee meetings.

Name: National Vaccine Advisory

Committee (NVAC).

Times and Dates: 9 a.m.–12:30 p.m.,

September 8, 1997; 8:30 a.m.–12 noon,

September 9, 1997.

Place: Hubert H. Humphrey Building,

Room 303A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Notice: In the interest of security, the

Department has instituted stringent

procedures for entrance to the Hubert H.

Humphrey Building by non-government

employees. Thus, persons without a

government identification card should plan

to arrive at the building each day either

between 8 and 8:30 a.m. or 12:30 and 1 p.m.

so they can be escorted to the meeting.

Entrance to the meeting at other times during

the day cannot be assured.

Purpose: This committee advises and

makes recommendations to the Director of

the National Vaccine Program on matters

related to the Program responsibilities.

Matters To Be Discussed: Agenda items

will include a National Vaccine Program

Office (NVPO) update; discussions on

immunization coverage: Strategies to sustain

success; accountability for immunization:

Closing the gaps; immunization registries:

Workshop plans; vaccine safety datalink:

Local and national perspectives; surveillance

for adverse events following vaccination:

Options for funding; mucosal vaccines:

Status, potential and current research;

utilization of non-traditional sites for adult

immunization; IPV/OPV: Impact of revised

recommendations on coverage; clarifying

harmonization of package labeling and

recommendations of advisory groups. There

will be an update on plans to address

concerns following the Edmonston-Zagreb

Measles Vaccine Investigation in Los

Angeles, California. Also, there will be

reports from the work group on philosophic

objections; reports from the Subcommittee on

Immunization Coverage; Subcommittee on

Future Vaccines; and the Subcommittee on

Vaccine Safety.

Name: Subcommittee on Immunization

Coverage.

Time and Date: 1:30 p.m.–5 p.m.,

September 8, 1997.

Place: Hubert H. Humphrey Building,

Room 423A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This subcommittee will identify

and propose solutions that provide a

multifaceted and holistic approach to

reducing barriers that result in low

immunization coverage for children.

Matters To Be Discussed: This

subcommittee will hold a discussion on the

review of recommendations from the

document, ‘‘Strategies to Sustain

Immunization Coverage’’, and the

finalization of those recommendations.

Name: Subcommittee on Future Vaccines.

Time And Date: 1:30 p.m.–5 p.m.,

September 8, 1997.

Place: Hubert H. Humphrey Building,

Room 405A, 00 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: The Subcommittee on Future

Vaccines will develop policy options and

guide national activities which will lead to

accelerated development, licensure, and best

use of new vaccines in the simplest possible

immunization schedules.

Matters To Be Discussed: This

subcommittee will hold discussions

regarding the Cold Spring Harbor Report;

combination vaccines, strategic options; and

defining future vaccines policy issues for

traveler’s vaccines.

Name: Subcommittee on Vaccine Safety

and the Advisory Commission on Childhood

Vaccines, Subcommittee on Vaccine Safety.

Time And Date: 1:15 p.m.–4:45 p.m.,

September 9, 1997.

Place: Hubert H. Humphrey Building,

Room 303A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This joint NVAC/ACCV

subcommittee will review issues relevant to

vaccine safety and adverse reactions to

vaccines.

Matters To Be Discussed: This

subcommittee will hold discussions

regarding the vaccine safety subcommittee

goals; a report from the Task Force on Safer

Childhood Vaccines; a project report on

benefit-risk communication curriculum

development; and agenda items for next

meeting.

Agenda items are subject to change as

priorities dictate.

Contact Person For More Information:

Felecia D. Pearson, Committee Management

Specialist, NVPO, CDC, 1600 Clifton Road,

NE, M/S D50, Atlanta, Georgia 30333,

telephone 404/639–7250.

Dated: August 18, 1997.

Nancy C. Hirsch,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–22470 Filed 8–21–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration for Children and

Families

Submission for OMB Review;

Comment Request

Title: Notice of Lien.

OMB No.: 0970–0153.

Description: Section 324 of PRWORA

’96 (Pub. L. 104–193), requires DHHS to

promulgate a standard lien form for use

by the State CSE programs to secure

delinquent child support obligations in

interstate cases.

Respondents: States.
44700 Federal Register / Vol. 62, No. 163 / Friday, August 22, 1997 / Notices

ANNUAL BURDEN ESTIMATES

Instrument Number of

respondents

Number of

responses

per respondent

Average

burden

hours per

response

Total burden hours

Lien ................................................................................................................................... 53,254 1 0.25 13,313

Estimated Total Annual Burden

Hours: 13,313.

Additional Information: Copies of the

proposed collection may be obtained by

writing to The Administration for

Children and Families, Office of

Information Services, Division of

Information Resource Management

Services, 370 L’Enfant Promenade, SW.,

Washington, DC 20447, Attn: ACF

Reports Clearance Officer.

OMB Comment: OMB is required to

make a decision concerning the

collection of information between 30

and 60 days after publication of this

document in the Federal Register.

Therefore, a comment is best assured of

having its full effect if OMB receives it

within 30 days of publication. Written

comments and recommendations for the

proposed information collection should

be sent directly to the following: Office

of Management and Budget, Paperwork

Reduction Project, 725 17th Street,

N.W., Washington, D.C. 20503, Attn:

Ms. Wendy Taylor.

Dated: August 18, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–22285 Filed 8–21–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration for Children and

Families

Submission for OMB Review;

Comment Request

Title: Administrative Subpoena.

OMB No.: 0970–0152.

Description:

Respondents: Individuals and

Households; not-for-profit institutions;

business or other for-profit; and State,

Local or Tribal Govt.

Annual Burden Estimates:

Instrument Number of

respondents

Number of

responses

per respondent

Average

burden

hours per

response

Total burden hours

Subpoena ......................................................................................................................... 15,391 1 0.5 7,696

Estimated Total Annual Burden

Hours: 7,696.

Additional Information: Copies of the

proposed collection may be obtained by

writing to The Administration for

Children and Families, Office of

Information Services, Division of

Information Resource Management

Services, 370 L’Enfant Promenade, SW.,

Washington, DC 20447, Attn: ACF

Reports Clearance Officer.

OMB Comment: OMB is required to

make a decision concerning the

collection of information between 30

and 60 days after publication of this

document in the Federal Register.

Therefore, a comment is best assured of

having its full effect if OMB receives it

within 30 days of publication. Written

comments and recommendations for the

proposed information collection should

be sent directly to the following: Office

of Management and Budget, Paperwork

Reduction Project, 725 17th Street, NW.,

Washington, DC 20503, Attn: Ms.

Wendy Taylor.

Dated: August 18, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–22286 Filed 8–21–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting will be closed to the public.

Name of Committee: General Hospital

and Personal Use Devices Panel of the

Medical Devices Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on September 15, 1997, 10 a.m. to

5:30 p.m., and September 16, 1997, 8

a.m. to 12 m.

Location: Holiday Inn, Walker/

Whetstone Rooms, Two Montgomery

Village Ave., Gaithersburg, MD.

Contact Person: Martha T. O’Lone,

Center for Devices and Radiological

Health (HFZ-480), Food and Drug

Administration, 9200 Corporate Blvd.,

Rockville, MD 20850, 301-443-8913, or

FDA Advisory Committee Information

Line, 1-800-741-8138 (301-443-0572 in

the Washington, DC area), code 12520.

Please call the Information Line for upto-date information on this meeting.

Agenda: On September 15 and 16,

1997, the committee will discuss and

make recommendations on the draft

guidance entitled ‘‘Testing for Skin

Sensitization to Chemicals in Latex

Products.’’ Single copies of this draft

guidance are available to the public

from the Division of Small

Manufacturers Assistance, 1350 Piccard

Dr., Rockville, MD 20851, 1-800-638-

2041, or on the Internet using the World

Wide Web (WWW) (http://

www.fda.gov/cdrh/draftgui.html).

Procedure: On September 15, 1997,

from 10:30 a.m. to 5:30 p.m., and

September 16, 1997, from 8 a.m. to 12

m., the meeting is open to the public.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Written submissions may be

made to the contact person by August 9,

1997. Oral presentations from the public

will be scheduled between

approximately 11 a.m. and 12 m. on

September 15, 1997. Time allotted for

each presentation may be limited. Those

desiring to make formal oral

presentations should notify the contact